603229 奥翔药业
已收盘 10-13 15:00:00
资讯
新帖
简况
奥翔药业（603229）9月23日主力资金净买入1517.80万元
证券之星 · 09-24
奥翔药业（603229）9月23日主力资金净买入1517.80万元
股市必读：奥翔药业中报 - 第二季度单季净利润同比下降53.78%
证券之星 · 08-31
股市必读：奥翔药业中报 - 第二季度单季净利润同比下降53.78%
每周股票复盘：奥翔药业（603229）Q2扣非净利亏损1188万
证券之星 · 08-30
每周股票复盘：奥翔药业（603229）Q2扣非净利亏损1188万
奥翔药业（603229）2026年中报简析：净利润同比下降29.23%，三费占比上升明显
证券之星 · 08-30
奥翔药业（603229）2026年中报简析：净利润同比下降29.23%，三费占比上升明显
奥翔药业(603229)6月30日股东户数2.62万户，较上期减少15.64%
证券之星 · 08-29
奥翔药业(603229)6月30日股东户数2.62万户，较上期减少15.64%
图解奥翔药业中报：第二季度单季净利润同比下降53.78%
证券之星 · 08-28
图解奥翔药业中报：第二季度单季净利润同比下降53.78%
股市必读：奥翔药业新发布《奥翔药业关于全资子公司获得药品注册证书的公告》
证券之星 · 08-24
股市必读：奥翔药业新发布《奥翔药业关于全资子公司获得药品注册证书的公告》
每周股票复盘：奥翔药业（603229）子公司获磷酸芦可替尼片注册证
证券之星 · 08-23
每周股票复盘：奥翔药业（603229）子公司获磷酸芦可替尼片注册证
奥翔药业最新公告：全资子公司获磷酸芦可替尼片药品注册证书
证券之星 · 08-21
奥翔药业最新公告：全资子公司获磷酸芦可替尼片药品注册证书
每周股票复盘：奥翔药业（603229）每股派现0.064元
证券之星 · 07-12
每周股票复盘：奥翔药业（603229）每股派现0.064元
奥翔药业（603229）披露2025年年度权益分派实施公告，7月9日股价下跌0.5%
证券之星 · 07-09
奥翔药业（603229）披露2025年年度权益分派实施公告，7月9日股价下跌0.5%
每周股票复盘：奥翔药业（603229）合作产品获英国上市许可
证券之星 · 07-05
每周股票复盘：奥翔药业（603229）合作产品获英国上市许可
奥翔药业（603229）披露合作产品获得境外上市许可公告，7月1日股价上涨5.17%
证券之星 · 07-01
奥翔药业（603229）披露合作产品获得境外上市许可公告，7月1日股价上涨5.17%
奥翔药业(603229.SH)：甲磺酸仑伐替尼胶囊获得英国上市许可
智通财经 · 06-30
奥翔药业(603229.SH)：甲磺酸仑伐替尼胶囊获得英国上市许可
每周股票复盘：奥翔药业（603229）合作产品获英国上市许可
证券之星 · 06-28
每周股票复盘：奥翔药业（603229）合作产品获英国上市许可
奥翔药业（603229）披露合作产品获得境外上市许可，6月25日股价下跌0.87%
证券之星 · 06-25
奥翔药业（603229）披露合作产品获得境外上市许可，6月25日股价下跌0.87%
奥翔药业(603229.SH)：合作产品哌柏西利片获得英国上市许可
智通财经 · 06-25
奥翔药业(603229.SH)：合作产品哌柏西利片获得英国上市许可
股市必读：奥翔药业（603229）6月23日董秘有最新回复
证券之星 · 06-24
股市必读：奥翔药业（603229）6月23日董秘有最新回复
奥翔药业：公司依托生物技术、AI技术赋能API及相关业务发展
证券之星 · 06-23
奥翔药业：公司依托生物技术、AI技术赋能API及相关业务发展
奥翔药业(603229.SH)获得氟伐他汀钠原料药上市申请批准通知书
智通财经 · 06-02
奥翔药业(603229.SH)获得氟伐他汀钠原料药上市申请批准通知书
加载更多
公司概况
公司名称：
浙江奥翔药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-05-09
主营业务：
浙江奥翔药业股份有限公司的主营业务是制剂、特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务。公司的主要产品是制剂、特色原料药及医药中间体。
发行价格：
7.81
{"stockData":{"symbol":"603229","market":"SH","secType":"STK","nameCN":"奥翔药业","latestPrice":7.93,"timestamp":1791874800000,"preClose":8.01,"halted":0,"volume":5820780,"delay":0,"changeRate":-0.01,"floatShares":830000000,"shares":830000000,"eps":0.0977,"marketStatus":"已收盘","change":-0.08,"latestTime":"10-13 15:00:00","open":7.93,"high":8.05,"low":7.73,"amount":45654100,"amplitude":0.04,"askPrice":7.93,"askSize":174,"bidPrice":7.92,"bidSize":147,"shortable":0,"etf":0,"ttmEps":0.0977,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791941400000},"marketStatusCode":5,"adr":0,"adjPreClose":8.01,"symbolType":"stock","openAndCloseTimeList":[[1791855000000,1791862200000],[1791867600000,1791874800000]],"highLimit":8.81,"lowLimit":7.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":830297145,"isCdr":false,"pbRate":2.76,"roa":"--","peRate":81.166837,"roe":"5.26%","epsLYR":0.16,"committee":0.019886,"marketValue":6584000000,"turnoverRate":0.007,"status":1,"floatMarketCap":6584000000},"requestUrl":"/m/hq/s/603229","defaultTab":"news","newsList":[{"id":"2669432224","title":"奥翔药业（603229）9月23日主力资金净买入1517.80万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669432224?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:18","pubTimestamp":1790209125,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，奥翔药业报收于8.4元，上涨3.58%，换手率3.36%，成交量27.89万手，成交额2.38亿元。近5日资金流向一览见下表：奥翔药业融资融券信息显示，融资方面，当日融资买入2063.31万元，融资偿还1317.09万元，融资净买入746.22万元，连续3日净买入累计801.71万元。奥翔药业主营业务：制剂、特色原料药及医药中间体的研发、生产与销售,以及为客户提供定制生产和研发业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663026670","title":"股市必读：奥翔药业中报 - 第二季度单季净利润同比下降53.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663026670","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663026670?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:59","pubTimestamp":1788141543,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，奥翔药业报收于8.03元，下跌0.25%，换手率0.52%，成交量4.32万手，成交额3477.24万元。业绩披露要点财务报告2026年中报显示，上半年度公司主营收入4.68亿元，同比下降2.96%；归母净利润1.2亿元，同比下降29.23%；扣非净利润8049.53万元，同比下降46.73%；其中2026年第二季度，单季度主营收入1.59亿元，同比下降9.3%；单季度归母净利润2317.83万元，同比下降53.78%；单季度扣非净利润-1188.3万元，同比下降130.02%；负债率22.37%，投资收益1076.61万元，财务费用3137.97万元，毛利率54.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100006014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663534043","title":"每周股票复盘：奥翔药业（603229）Q2扣非净利亏损1188万","url":"https://stock-news.laohu8.com/highlight/detail?id=2663534043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663534043?lang=zh_cn&edition=full","pubTime":"2026-08-30 07:05","pubTimestamp":1788044716,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，奥翔药业报收于8.03元，较上周的8.1元下跌0.86%。业绩披露要点财务报告奥翔药业2026年中报显示，上半年主营收入4.68亿元，同比下降2.96%；归母净利润1.2亿元，同比下降29.23%；扣非净利润8049.53万元，同比下降46.73%。奥翔药业2026年半年度募集资金存放、管理与实际使用情况的专项报告2020年度非公开发行股票募集资金净额40,794.04万元，截至2026年6月30日累计投入37,652.81万元，期末余额4,147.09万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000003693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048901","title":"奥翔药业（603229）2026年中报简析：净利润同比下降29.23%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048901","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048901?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:11","pubTimestamp":1788041485,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期奥翔药业发布2026年中报。截至本报告期末，公司营业总收入4.68亿元，同比下降2.96%，归母净利润1.2亿元，同比下降29.23%。按单季度数据看，第二季度营业总收入1.59亿元，同比下降9.3%，第二季度归母净利润2317.83万元，同比下降53.78%。本报告期奥翔药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达124.72%。然而去年的净利率为16.47%，算上全部成本后，公司产品或服务的附加值高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663125120","title":"奥翔药业(603229)6月30日股东户数2.62万户，较上期减少15.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663125120","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663125120?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:08","pubTimestamp":1787994516,"startTime":"0","endTime":"0","summary":"证券之星消息，近日奥翔药业披露，截至2026年6月30日公司股东户数为2.62万户，较3月31日减少4851.0户，减幅为15.64%。在化学制药行业个股中，奥翔药业股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，奥翔药业区间跌幅为23.52%，在此期间股东户数减少4851.0户，减幅为15.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064696","title":"图解奥翔药业中报：第二季度单季净利润同比下降53.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064696","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662064696?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:42","pubTimestamp":1787913769,"startTime":"0","endTime":"0","summary":"证券之星消息，奥翔药业2026年中报显示，上半年度公司主营收入4.68亿元，同比下降2.96%；归母净利润1.2亿元，同比下降29.23%；扣非净利润8049.53万元，同比下降46.73%；其中2026年第二季度，公司单季度主营收入1.59亿元，同比下降9.3%；单季度归母净利润2317.83万元，同比下降53.78%；单季度扣非净利润-1188.3万元，同比下降130.02%；负债率22.37%，投资收益1076.61万元，财务费用3137.97万元，毛利率54.13%。财报数据概要请见下图:本文数据来源于奥翔药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661246854","title":"股市必读：奥翔药业新发布《奥翔药业关于全资子公司获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661246854","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661246854?lang=zh_cn&edition=full","pubTime":"2026-08-24 04:46","pubTimestamp":1787517972,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，奥翔药业报收于8.1元，下跌2.99%，换手率1.4%，成交量11.66万手，成交额9481.89万元。公司公告汇总奥翔药业关于全资子公司获得药品注册证书的公告浙江奥翔药业股份有限公司全资子公司浙江麒正药业有限公司近日收到国家药品监督管理局核准签发的磷酸芦可替尼片《药品注册证书》，规格为5mg、15mg、20mg，注册分类为化学药品4类，视同通过仿制药一致性评价。截至目前，公司对该产品累计研发投入约1911万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661214966","title":"每周股票复盘：奥翔药业（603229）子公司获磷酸芦可替尼片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2661214966","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661214966?lang=zh_cn&edition=full","pubTime":"2026-08-23 04:05","pubTimestamp":1787429113,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，奥翔药业报收于8.1元，较上周的8.37元下跌3.23%。本周，奥翔药业8月20日盘中最高价报8.53元。本周关注点公司公告汇总：全资子公司获磷酸芦可替尼片药品注册证书公司公告汇总奥翔药业全资子公司浙江麒正药业有限公司收到国家药监局核准签发的磷酸芦可替尼片《药品注册证书》，规格为5mg、15mg、20mg，注册分类为化学药品4类，视同通过仿制药一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661641322","title":"奥翔药业最新公告：全资子公司获磷酸芦可替尼片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2661641322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661641322?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:27","pubTimestamp":1787308037,"startTime":"0","endTime":"0","summary":"奥翔药业(603229.SH)公告称，公司全资子公司麒正药业收到国家药监局核准签发的磷酸芦可替尼片《药品注册证书》，该药品适用于治疗中危或高危的原发性骨髓纤维化等适应症。本次获批视同通过仿制药一致性评价，对公司未来发展带来积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100034464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650124154","title":"每周股票复盘：奥翔药业（603229）每股派现0.064元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650124154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650124154?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:42","pubTimestamp":1783795329,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，奥翔药业报收于8.09元，较上周的8.46元下跌4.37%。本周，奥翔药业7月6日盘中最高价报8.71元。本次利润分配以总股本830,297,145股扣除回购股份后825,095,945股为基数，向全体股东每10股派发现金红利0.64元（含税），合计派发现金红利52,806,140.48元（含税）。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650783639","title":"奥翔药业（603229）披露2025年年度权益分派实施公告，7月9日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650783639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650783639?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:35","pubTimestamp":1783607715,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，奥翔药业报收于7.91元，较前一交易日下跌0.5%，最新总市值为65.68亿元。该股当日开盘7.9元，最高8.12元，最低7.8元，成交额达5135.96万元，换手率为0.78%。近日，奥翔药业发布《2025年年度权益分派实施公告》：每股现金红利0.064元（含税），不送红股，不进行资本公积金转增股本。股权登记日为2026年7月16日，除权（息）日及现金红利发放日均为2026年7月17日。公司回购专用账户中的股份不参与利润分配。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649769263","title":"每周股票复盘：奥翔药业（603229）合作产品获英国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2649769263","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649769263?lang=zh_cn&edition=full","pubTime":"2026-07-05 03:45","pubTimestamp":1783194313,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，奥翔药业报收于8.46元，较上周的7.74元上涨9.3%。本周，奥翔药业7月3日盘中最高价报8.48元。本周关注点公司公告汇总：奥翔药业合作产品甲磺酸仑伐替尼胶囊获英国上市许可。公司公告汇总奥翔药业关于合作产品获得境外上市许可的公告浙江奥翔药业股份有限公司合作伙伴STADA的子公司THORTON & ROSS LIMITED近日收到英国药品和健康产品管理局核准签发的甲磺酸仑伐替尼胶囊上市许可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648563514","title":"奥翔药业（603229）披露合作产品获得境外上市许可公告，7月1日股价上涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648563514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648563514?lang=zh_cn&edition=full","pubTime":"2026-07-01 18:04","pubTimestamp":1782900277,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，奥翔药业报收于8.14元，较前一交易日上涨5.17%，最新总市值为67.59亿元。该股当日开盘7.7元，最高8.16元，最低7.64元，成交额达8843.38万元，换手率为1.34%。奥翔药业于近日披露《关于合作产品获得境外上市许可的公告》。公告显示，公司合作伙伴STADA的子公司THORTON & ROSS LIMITED近日收到英国药品和健康产品管理局核准签发的甲磺酸仑伐替尼胶囊上市许可。甲磺酸仑伐替尼胶囊为多靶点酪氨酸激酶抑制剂，用于多种癌症治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100035177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647536258","title":"奥翔药业(603229.SH)：甲磺酸仑伐替尼胶囊获得英国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2647536258","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647536258?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:51","pubTimestamp":1782809476,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥翔药业 发布公告，近日，公司合作伙伴STADA Arzneimittel AG的子公司THORNTON & ROSS LIMITED 收到英国药品和健康产品管理局核准签发的甲磺酸仑伐替尼胶囊上市许可。甲磺酸仑伐替尼胶囊是多靶点酪氨酸激酶抑制剂。作为常用抗血管生成靶向药，仑伐替尼可选择性抑制VEGFR、FGFR等多类激酶，阻断肿瘤血管生成通路，抑制血管新生与肿瘤增殖，具备广谱抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603229","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646131571","title":"每周股票复盘：奥翔药业（603229）合作产品获英国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2646131571","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646131571?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:52","pubTimestamp":1782589933,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，奥翔药业报收于7.74元，较上周的8.12元下跌4.68%。本周，奥翔药业6月23日盘中最高价报8.35元。本周关注点公司公告汇总：奥翔药业合作产品哌柏西利片获英国上市许可。公司公告汇总奥翔药业关于合作产品获得境外上市许可的公告浙江奥翔药业股份有限公司合作伙伴STADA的子公司THORNTON & ROSS LIMITED近日收到英国药品和健康产品管理局核准签发的哌柏西利片上市许可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646025809","title":"奥翔药业（603229）披露合作产品获得境外上市许可，6月25日股价下跌0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646025809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646025809?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:47","pubTimestamp":1782398833,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，奥翔药业报收于8.02元，较前一交易日下跌0.87%，最新总市值为66.59亿元。该股当日开盘8.06元，最高8.15元，最低7.81元，成交额达4769.44万元，换手率为0.72%。近日，奥翔药业发布《关于合作产品获得境外上市许可的公告》。公告显示，公司合作伙伴STADA的子公司THORNTON & ROSS LIMITED近日收到英国药品和健康产品管理局核准签发的哌柏西利片上市许可。该产品为公司与STADA合作开发的制剂产品，公司负责生产，双方在各自市场区域开展销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646770879","title":"奥翔药业(603229.SH)：合作产品哌柏西利片获得英国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2646770879","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646770879?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:00","pubTimestamp":1782381650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥翔药业 发布公告，近日，公司合作伙伴STADA Arzneimittel AG的子公司THORNTON & ROSS LIMITED收到英国药品和健康产品管理局核准签发的哌柏西利片上市许可。该制剂产品系公司与STADA合作共同开发和商业化的产品之一，公司承担该制剂产品的生产任务，而销售工作则由双方在各自负责的市场区域分别开展。据悉，哌柏西利片是一种细胞周期蛋白依赖性激酶CDK4/6抑制剂，适用于治疗激素受体(HR+)阳性、人表皮生长因子受体2阴性的局部晚期或转移性乳腺癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603229","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645855241","title":"股市必读：奥翔药业（603229）6月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645855241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645855241?lang=zh_cn&edition=full","pubTime":"2026-06-24 02:50","pubTimestamp":1782240622,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，奥翔药业报收于8.24元，上涨3.65%，换手率1.23%，成交量10.2万手，成交额8366.64万元。董秘最新回复投资者： 董秘您好，公司已布局AI技术用于靶点发现、化合物筛选与合成工艺优化，同时推进创新药管线与CDMO业务。董秘： 投资者您好：公司依托生物技术、AI技术赋能API及相关业务发展，相关布局与应用思路可查阅公司2025年年度报告。当日关注点交易信息汇总：6月23日主力资金净流入746.0万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400001678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645863248","title":"奥翔药业：公司依托生物技术、AI技术赋能API及相关业务发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2645863248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645863248?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:33","pubTimestamp":1782199996,"startTime":"0","endTime":"0","summary":"证券之星消息，奥翔药业06月23日在投资者关系平台上答复投资者关心的问题。奥翔药业回复：投资者您好：公司依托生物技术、AI技术赋能API及相关业务发展，相关布局与应用思路可查阅公司2025年年度报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300020939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640160169","title":"奥翔药业(603229.SH)获得氟伐他汀钠原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2640160169","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640160169?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:14","pubTimestamp":1780391671,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥翔药业(603229.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的氟伐他汀钠原料药的《化学原料药上市申请批准通知书》。氟伐他汀钠是一种全合成羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂，适用于治疗原发性高胆固醇血症、混合型血脂异常，也可用于冠心病及冠心病等危症患者的血脂调控，延缓动脉粥样硬化进展，降低心肌梗死、缺血性卒中等心脑血管不良事件风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603229","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791878403539,"stockEarnings":[{"period":"1week","weight":-0.0303},{"period":"1month","weight":0.0652},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.2128},{"period":"1year","weight":-0.2065},{"period":"ytd","weight":-0.1866}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江奥翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26169人(较上一季度减少15.64%)","perCapita":"31728股","listingDate":"2017-05-09","address":"浙江省台州市临海市化学原料药基地临海园区东海第四大道5号","registeredCapital":"83029万元","survey":" 浙江奥翔药业股份有限公司的主营业务是制剂、特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务。公司的主要产品是制剂、特色原料药及医药中间体。","listedPrice":7.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥翔药业(603229)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥翔药业(603229)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥翔药业,603229,奥翔药业股票,奥翔药业股票老虎,奥翔药业股票老虎国际,奥翔药业行情,奥翔药业股票行情,奥翔药业股价,奥翔药业股市,奥翔药业股票价格,奥翔药业股票交易,奥翔药业股票购买,奥翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥翔药业(603229)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥翔药业(603229)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}